LogicBio Therapeutics, Inc. (LOGC) Social Stream
LogicBio Therapeutics Inc (LOGC) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering LogicBio Therapeutics Inc.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
LOGC's average price target has moved down $1.45 over the prior 156 days.
Over the past 16 months, LOGC's average upside potential has been 261.27%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
LOGC Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for LOGC as an investment opportunity.
- LOGC has a greater upside potential (average analyst target price relative to current price) than 295.77% of all US stocks.
- LogicBio Therapeutics Inc's average analyst price target is greater than 77.04% of all US stocks.
- The number of analysts covering the stock of LOGC is higher than 95.35% of all US stocks.
- The variance in analysts' estimates of LOGC is lower than 2.5% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, SBTX, VTYX and ONCR are the three stocks most similar to LogicBio Therapeutics Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding LOGC using the data that counts. Try POWR Ratings for free.